“Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s26. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/172.